



## **Cytokinetics COURAGE-ALS trial**

In collaboration with our academic partner TRICALS, Cytokinetics is conducting a Phase 3 trial to determine the safety and efficacy of their investigational drug reldesemtiv for the treatment of ALS.

### **Reldesemtiv**

Reldesemtiv was developed by Cytokinetics in order to counteract the decline in muscle function. In a Phase 2 study, the drug was tested in people with ALS for a 12 week period. The current study is testing its effectiveness in the longer term and in a larger group of people.

All information on the study design, entry criteria and participating TRICALS centers can be found [here at the TRICALS website](#).

### **EUpALS**

Kapucijnenvoer 33 B/1, B-3000 Leuven, Belgium  
Tel: +32 (0)16-23 95 82 – Fax: +32 (0)16-29 98 65  
[info@ALS.eu](mailto:info@ALS.eu) – [ALS.eu](http://ALS.eu)